Olanzapine-induced weight gain plays a key role in the potential cardiovascular risk: Evidence from heart rate variability analysis

Scientific Reports

Volumn 4, Issue , 2014, Pages

  Wang, Jun ^a   Liu, Yan Song ^a   Zhu, Wen Xian ^a   Zhang, Fu Quan ^a   Zhou, Zhen He ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; NEUROLEPTIC AGENT; OLANZAPINE; SEROTONIN UPTAKE INHIBITOR;

ADULT; BODY MASS; CARDIOVASCULAR DISEASES; CHINA; COMPLICATION; DRUG EFFECTS; FEMALE; HEART RATE; HUMAN; MALE; PATHOPHYSIOLOGY; RISK FACTOR; SCHIZOPHRENIA; WEIGHT GAIN;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY MASS INDEX; CARDIOVASCULAR DISEASES; CHINA; FEMALE; HEART RATE; HUMANS; MALE; RISK FACTORS; SCHIZOPHRENIA; SEROTONIN UPTAKE INHIBITORS; WEIGHT GAIN;

EID: 84923337257     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep07394     Document Type: Article

References (28)

1. Brown, S., Kim, M., Mitchell, C. & Inskip, H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry 196, 116-121 (2010
2. Healy, D. et al. Mortality in schizophrenia and related psychoses: data from two cohorts, 1875-1924 and 1994-2010. BMJ Open 2, e001810 (2012
3. Koponen, H. et al. Schizophrenia and sudden cardiac death: a review. Nord J Psychiatry 62, 342-345 (2008
4. Ifteni, P., Correll, C. U., Burtea, V., Kane, J. M. & Manu, P. Sudden unexpected death in schizophrenia: autopsy findings in psychiatric inpatients. Schizophr Res 155, 72-76 (2014
5. Lin, S. T. et al. Association Between Antipsychotic Use and Risk of Acute Myocardial Infarction: A Nationwide Case-Crossover Study. Circulation 130, 235-243 (2014
6. Ray, W. A., Chung, C. P., Murray, K. T., Hall, K. & Stein, C. M. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 360, 225-235 (2009
7. Leung, J. Y., Barr, A. M., Procyshyn, R. M., Honer, W. G. & Pang, C. C. Cardiovascular side-effects of antipsychotic drugs: the role of the autonomic nervous system. Pharmacol Ther 135, 113-122 (2012
8. Thayer, J. F., Yamamoto, S. S. & Brosschot, J. F. The relationship of autonomic imbalance, heart rate variability and cardiovascular disease risk factors. Int J Cardiol 141, 122-131 (2010
9. Heart rate variability: standards ofmeasurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation 93, 1043-1065 (1996
10. Huikuri, H. V. et al. Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction. Eur Heart J 30, 689-698 (2009
11. Fujibayashi, M. et al. Autonomic nervous system activity and psychiatric severity in schizophrenia. Psychiatry Clin Neurosci 63, 538-545 (2009
12. Moon, E., Lee, S. H., Kim, D. H. & Hwang, B. Comparative Study of Heart Rate Variability in Patients with Schizophrenia, Bipolar Disorder, Post-traumatic Stress Disorder, or Major Depressive Disorder. Clin Psychopharmacol Neurosci 11, 137-143 (2013
13. Bar, K. J. et al. Loss of efferent vagal activity in acute schizophrenia. J Psychiatr Res 39, 519-527 (2005
14. Toichi, M. et al. The influence of psychotic states on the autonomic nervous system in schizophrenia. Int J Psychophysiol 31, 147-154 (1999
15. Cohen, H., Loewenthal, U., Matar, M. & Kotler, M. Association of autonomic dysfunction and clozapine. Heart rate variability and risk for sudden death in patients with schizophrenia on long-term psychotropic medication. Br J Psychiatry 179, 167-171 (2001
16. Rechlin, T., Beck, G., Weis, M. & Kaschka, W. P. Correlation between plasma clozapine concentration and heart rate variability in schizophrenic patients. Psychopharmacology (Berl) 135, 338-341 (1998
17. Mann, K. et al. Heart rate variability during sleep in patients with schizophrenia treated with olanzapine. Int Clin Psychopharmacol 19, 325-330 (2004
18. Bar, K. J. et al. Influence of olanzapine on QT variability and complexity measures of heart rate in patients with schizophrenia. J Clin Psychopharmacol 28, 694-698 (2008
19. Silke, B., Campbell, C. & King, D. J. The potential cardiotoxicity of antipsychotic drugs as assessed by heart rate variability. J Psychopharmacol 16, 355-360 (2002
20. Srihari, V. H. et al. Cardiovascular mortality in schizophrenia: defining a critical period for prevention. Schizophr Res 146, 64-68 (2013
21. Adachi, T. et al. Effect of weight gain on cardiac autonomic control during wakefulness and sleep. Hypertension 57, 723-730 (2011
22. Karason, K., Molgaard, H., Wikstrand, J. & Sjostrom, L. Heart rate variability in obesity and the effect of weight loss. Am J Cardiol 83, 1242-1247 (1999
23. Anath, J. et al. Weight gain associated with atypical antipsychotic drugs: mechanisms and management. Expert Rev Neurother 3, 59-68 (2003
24. Lipkovich, I., Jacobson, J. G., Hardy, T. A. & Hoffmann, V. P. Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder. BMC Psychiatry 8, 78 (2008
25. Valkonen-Korhonen, M. et al. Heart rate variability in acute psychosis. Psychophysiology 40, 716-726 (2003
26. Bryden, K. E. & Kopala, L. C. Body mass index increase of 58% associated with olanzapine. Am J Psychiatry 156, 1835-1836 (1999
27. Bobo, W. V., Bonaccorso, S., Jayathilake, K. & Meltzer, H. Y. Prediction of longterm metabolic effects of olanzapine and risperidone treatment from baseline body mass index in schizophrenia and bipolar disorder. Psychiatry Res 189, 200-207 (2011
28. Pagani, M. et al. Power spectral analysis of heart rate and arterial pressure variabilities as amarker of sympatho-vagal interaction in man and conscious dog. Circ Res 59, 178-193 (1986).